```html

Lupus Pernio (Cutaneous Sarcoidosis)

Overview

Lupus pernio is a chronic, disfiguring form of cutaneous sarcoidosis that primarily affects the skin of the face, especially the nose, cheeks, ears, and lips. It appears as violaceous (purple‑bluish), thickened plaques or nodules that can become raised, indurated, and sometimes ulcerated. The condition is part of a systemic granulomatous disease called sarcoidosis, in which immune cells form non‑caseating granulomas in multiple organs.

Who it affects: Lupus pernio most commonly occurs in adults between 30 and 60 years of age, with a strong predilection for women (about 2–3 : 1 female‑to‑male ratio). It is more prevalent among people of African, Scandinavian, or Caribbean descent. While any ethnicity can develop sarcoidosis, those groups are over‑represented in epidemiologic studies.

Prevalence: Cutaneous sarcoidosis occurs in roughly 20–35 % of patients with systemic sarcoidosis. Lupus pernio is the least common cutaneous presentation, seen in about 5–10 % of all sarcoidosis cases, translating to an estimated 1–2 cases per 100,000 people in the United States (CDC, 2023).

Symptoms

Symptoms of lupus pernio can vary from subtle discoloration to extensive, painful plaques. The most characteristic findings are:

• Violaceous or erythematous plaques on the nose, cheeks, ears, or lips. The lesions are often symmetrical.
• Induration (hardening) – the skin feels firm to the touch because of underlying granulomatous inflammation.
• Swelling and edema of the affected area, which may cause a “bulky” appearance.
• Ulceration or crusting – in severe disease the plaques can break down, leading to painful sores.
• Itching or burning sensation – many patients report mild pruritus or a burning feeling.
• Nasolabial fold distortion – chronic lesions can cause permanent changes in facial contours.
• Functional impairment – severe nasal involvement may obstruct airflow; ear lesions can affect hearing or cause vestibular symptoms.
• Systemic symptoms (when sarcoidosis involves other organs): fatigue, fever, weight loss, shortness of breath, dry cough, joint pain, or eye redness.

Causes and Risk Factors

The exact cause of lupus pernio is unknown, but research points to a complex interaction of genetic, immunologic, and environmental factors.

Underlying Mechanism

• Immune dysregulation: Over‑activation of CD4+ T‑helper cells and macrophages leads to formation of non‑caseating granulomas in the skin and other organs.
• Genetic susceptibility: Certain HLA alleles (e.g., HLA‑DRB1*03, HLA‑DRB1*15) are associated with a higher risk of chronic cutaneous sarcoidosis.
• Environmental triggers: Occupational exposure to inorganic dusts (e.g., silica, beryllium), insecticides, or organic solvents may precipitate disease in predisposed individuals.
• Infectious agents: Mycobacteria, Propionibacterium acnes, and certain viruses have been detected in granulomas, suggesting a possible role as antigenic triggers, though causality remains unproven.

Risk Factors

• Female sex (2–3 × higher risk)
• Age 30‑60 years
• African‑American, Scandinavian, or Caribbean ancestry
• Family history of sarcoidosis or other granulomatous diseases
• Occupational exposure to silica, beryllium, or metal dusts
• Smoking is not a strong risk factor for sarcoidosis, but it can worsen pulmonary involvement.

Diagnosis

Diagnosing lupus pernio involves a combination of clinical evaluation, skin biopsy, and systemic work‑up to assess for extracutaneous sarcoidosis.

Step‑by‑step diagnostic approach

1. Clinical examination – Dermatologists look for the classic violaceous plaques on the nose, cheeks, or ears.
2. Skin biopsy – A 4‑mm punch or incisional biopsy is taken from the active margin of a lesion. Histology typically shows:
   • Non‑caseating granulomas composed of epithelioid macrophages and multinucleated giant cells.
   • Absence of necrosis (distinguishes from infections like tuberculosis).
   • Sometimes inclusion bodies (Schaumann bodies or asteroid bodies) that support sarcoidosis.
3. Laboratory tests:
   • Serum angiotensin‑converting enzyme (ACE) – elevated in ~60 % of active sarcoidosis.
   • Calcium level – hypercalcemia may indicate systemic disease.
   • Complete blood count, liver function, and renal panel to assess organ involvement.
4. Imaging:
   • Chest X‑ray or high‑resolution CT scan – looks for hilar lymphadenopathy or pulmonary infiltrates.
   • FDG‑PET or Gallium scan – useful for detecting active granulomas in other organs.
5. Additional organ evaluation (based on symptoms):
   • Ophthalmology exam – to rule out uveitis.
   • Pulmonary function tests – assess lung involvement.
   • Cardiac MRI or ECG – if cardiac sarcoidosis is suspected.

Diagnosis is confirmed when clinical features and histology are consistent, and other granulomatous diseases (e.g., tuberculosis, fungal infections) are excluded.

Treatment Options

Lupus pernio is notoriously resistant to therapy, and treatment often requires a multimodal approach.

First‑line Medications

• Topical corticosteroids – high‑potency steroids (clobetasol 0.05 %) applied twice daily for 4–6 weeks can improve early lesions.
• Intralesional corticosteroid injections – triamcinolone acetonide (10 mg/mL) injected monthly may reduce plaque thickness.

Systemic Therapies

1. Oral corticosteroids – Prednisone 20–40 mg daily is often the first systemic step for moderate‑severe disease; tapering is attempted after 2–3 months.
2. Antimalarials (hydroxychloroquine 200–400 mg daily) – Helpful for many cutaneous forms, but lupus pernio often requires additional agents.
3. Immunosuppressants:
   • Methotrexate 10–25 mg weekly (folic acid supplementation required) – evidence shows ~60 % response in chronic cutaneous sarcoidosis.
   • Azathioprine 2–2.5 mg/kg/day – useful when steroids are contraindicated.
   • Mycophenolate mofetil 1–2 g/day – a newer option with favorable safety profile.
4. Biologic agents – Reserved for refractory disease:
   • TNF‑α inhibitors (infliximab 5 mg/kg IV at weeks 0, 2, 6 then every 8 weeks; or adalimumab 40 mg SC every other week) have demonstrated 70‑80 % remission rates in lupus pernio (J Am Acad Dermatol, 2021).
   • Ustekinumab (IL‑12/23 blocker) – limited case series show benefit.

Procedural Options

• Laser therapy – Pulsed dye laser (PDL) or CO₂ laser can improve erythema and scar tissue.
• Cryotherapy – May be used for isolated nodules.
• Photodynamic therapy (PDT) – Emerging evidence suggests benefit when combined with topical photosensitizers.

Lifestyle & Supportive Measures

• Sun protection – UV exposure can exacerbate skin lesions; use broad‑spectrum SPF 30+ sunscreen.
• Smoking cessation – improves overall pulmonary health and may enhance medication response.
• Stress management – chronic inflammation can be worsened by high stress; consider mindfulness, yoga, or counseling.
• Nutritional support – Adequate calcium/vitamin D intake if on long‑term steroids; avoid excessive calcium supplementation if hypercalcemia is present.

Living with Lupus Pernio (Cutaneous Sarcoidosis)

Managing a chronic, visible skin condition can be challenging both physically and emotionally. Below are practical tips to maintain quality of life.

Skin Care Routine

• Cleanse gently with fragrance‑free, non‑comedogenic cleanser twice daily.
• Apply prescribed topical agents after cleansing; allow 15 minutes before makeup.
• Moisturize with hypoallergenic, petrolatum‑based ointments to prevent dryness caused by steroids.

Cosmetic Camouflage

Dermatologic‑grade camouflage makeup (e.g., color‑correcting kits) can significantly reduce psychosocial distress. Seek guidance from a makeup artist familiar with skin conditions.

Follow‑up Schedule

• Dermatology appointments every 3 months initially, then every 6–12 months once stable.
• Annual ophthalmology exam if on systemic steroids or antimalarials.
• Pulmonary function testing every 1–2 years if any lung involvement was noted.

Emotional & Social Support

• Join sarcoidosis patient support groups (e.g., American Lung Association Sarcoidosis Community).
• Consider cognitive‑behavioral therapy (CBT) to address anxiety or depression linked to chronic disease.
• Open communication with family and coworkers about your condition can reduce misunderstandings.

Work & Daily Activities

• If facial lesions cause visual obstruction or breathing difficulty, discuss workplace accommodations (e.g., flexible hours, remote work).
• Plan for medication side‑effects: carry a list of drugs, dosage, and any known allergies.
• Stay physically active; moderate exercise improves overall immune regulation.

Prevention

Because the exact cause is unknown, primary prevention is limited. However, the following measures may reduce the risk of disease onset or exacerbation:

• Minimize exposure to occupational dusts and chemicals – use protective masks, adequate ventilation, and follow safety guidelines.
• Maintain a healthy immune system – balanced diet rich in omega‑3 fatty acids, regular exercise, adequate sleep.
• Avoid unnecessary UV exposure – wear hats, sunscreen, and protective clothing when outdoors.
• Prompt treatment of respiratory infections – some data suggest infections can trigger sarcoid flares.

Complications

If left untreated or inadequately controlled, lupus pernio can lead to several serious outcomes:

• Permanent disfigurement – fibrotic scarring may cause lasting facial contour changes.
• Nasolacrimal duct obstruction – swelling around the nose can block tear drainage, leading to chronic conjunctivitis.
• Airway obstruction – severe nasal involvement may impair breathing and increase infection risk.
• Systemic sarcoidosis progression – cutaneous disease often parallels internal organ involvement (lungs, eyes, heart, nervous system).
• Medication toxicity – long‑term steroids can cause osteoporosis, diabetes, hypertension; immunosuppressants carry infection risk.
• Psychosocial impact – facial lesions can cause low self‑esteem, social withdrawal, or depression.

When to Seek Emergency Care

References

• Mayo Clinic. “Sarcoidosis.” https://www.mayoclinic.org/diseases‑conditions/sarcoidosis/diagnosis‑treatment
• Centers for Disease Control and Prevention (CDC). “Sarcoidosis Data and Statistics.” 2023.
• National Institutes of Health (NIH). “Sarcoidosis: Clinical Presentation & Management.” 2022.
• World Health Organization (WHO). “Guidelines for the Diagnosis and Management of Sarcoidosis.” 2021.
• Cleveland Clinic. “Cutaneous Sarcoidosis (Lupus Pernio).” https://my.clevelandclinic.org/health/diseases/14991‑cutaneous‑sarcoidosis
• J Am Acad Dermatol. “TNF‑α Inhibitors in Refractory Lupus Pernio: A Multicenter Cohort Study.” 2021.

```